中度蛋白尿组分娩孕周比重度及大量蛋白尿组高；
Parturients with mild proteinuria were delivered later than parturients with severe proteinuria.
微量白蛋白尿组发生联合终点事件的机率较正常UACR组高43%。
Patients with microalbuminuria were 43 percent more likely to reach the combined end point than those with normal UACR.
大量白蛋白尿组发生联合终点事件的机率较正常UACR组高75%。
Patients with macroalbuminuria were 75 percent more likely to reach the combined end point than those with regular UACR.
与正常白蛋白尿组相比，UACR升高的患者年龄较大，有较多的心血管病，肾功能较差，糖尿病发生率较高。
Patients with increased UACR were older, had more cardiovascular disease, inferior kidney function, and a higher prevalence of diabetes than did those with normoalbuminuria.
巨量白蛋白尿的患者组，其肾病进展的危险因素与微量白蛋白尿组相似，其进展的患者肾小球滤过率较低（GFRs）且诊断有心血管疾病或心力衰竭。
The macroalbuminuria group had risk factors similar to the microalbuminuria group, and had lower glomerular filtration rates (GFRs) and a diagnosis of cardiovascular disease or heart failure.
结论：奥美沙坦与微量蛋白尿延缓出现有关，尽管基于现行标准，两组患者的血压控制情况均较好。
CONCLUSIONS: Olmesartan was associated with a delayed onset of microalbuminuria, even though blood-pressure control in both groups was excellent according to current standards.
结果在12周，三组的蛋白尿和血压没有明显差异。
Results At week 12, there were similar urinary protein excretion and SBP during three groups.
但之后统计的数据均提示，奥美沙坦组出现微量白蛋白尿的患者少于安慰剂组。
For the remainder of the study, fewer patients in the olmesartan group experienced microalbuminuria, compared with patients in the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
这意味着与安慰剂组相比，奥美沙坦组出现微量白蛋白尿的风险降低了23%。
This translated into a risk reduction of 23% for the olmesartan group, compared with the placebo group.
应用推荐